Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies targeting solid tumors. Its lead product, ficerafusp alfa, combines EGFR inhibition with TGF-β blockade to enhance anti-tumor activity, overcome resistance, and improve tolerability. Focused on cancers like head and neck squamous cell carcinoma, the company aims to deliver targeted, durable treatments that modulate the tumor microenvironment and activate immune responses.
This description was generated via AI from an annual report. Updated about 1 year ago.